The Diagnosis and Management of Dementia with Lewy Bodies (DLB) is a consensus report by the DLB Consortium, updated from the previous 2005 report. The report outlines revised diagnostic criteria and management strategies for DLB, emphasizing the distinction between clinical features and diagnostic biomarkers. Key diagnostic features include fluctuating cognition, visual hallucinations, and Parkinsonism, while biomarkers such as reduced dopamine transporter (DAT) uptake and metaiodobenzylguanidine (MIBG) scintigraphy are also important. The report also highlights the importance of REM sleep behavior disorder (RBD) and the need for careful evaluation of patients with dementia to avoid misdiagnosis as Alzheimer's disease. The report recommends a multidisciplinary approach to management, with a focus on non-pharmacological interventions and the use of cholinesterase inhibitors for cognitive symptoms. The report also emphasizes the need for further research into the underlying biology of DLB, including genetic and molecular factors, and the development of clinical trials for both symptomatic and disease-modifying treatments. The report concludes with a call for global collaboration to improve DLB research and patient care.The Diagnosis and Management of Dementia with Lewy Bodies (DLB) is a consensus report by the DLB Consortium, updated from the previous 2005 report. The report outlines revised diagnostic criteria and management strategies for DLB, emphasizing the distinction between clinical features and diagnostic biomarkers. Key diagnostic features include fluctuating cognition, visual hallucinations, and Parkinsonism, while biomarkers such as reduced dopamine transporter (DAT) uptake and metaiodobenzylguanidine (MIBG) scintigraphy are also important. The report also highlights the importance of REM sleep behavior disorder (RBD) and the need for careful evaluation of patients with dementia to avoid misdiagnosis as Alzheimer's disease. The report recommends a multidisciplinary approach to management, with a focus on non-pharmacological interventions and the use of cholinesterase inhibitors for cognitive symptoms. The report also emphasizes the need for further research into the underlying biology of DLB, including genetic and molecular factors, and the development of clinical trials for both symptomatic and disease-modifying treatments. The report concludes with a call for global collaboration to improve DLB research and patient care.